CeriBell, Inc. Announces Pricing of Upsized Initial Public Offering
CeriBell, Inc. (Nasdaq: CBLL), a commercial-stage medical technology company, has announced the pricing of its upsized initial public offering. The company is offering 10,606,060 shares of common stock at a public offering price of $17.00 per share. CeriBell has also granted underwriters a 30-day option to purchase up to an additional 1,590,909 shares at the initial offering price.
Trading of the shares is expected to begin on the Nasdaq Global Select Market on October 11, 2024, under the ticker symbol 'CBLL'. The gross proceeds from the offering are anticipated to be approximately $180.3 million, excluding any exercise of the underwriters' option. The offering is expected to close on October 15, 2024, subject to customary closing conditions.
BofA Securities and J.P. Morgan are acting as joint book-running managers and representatives of the underwriters, with William Blair, TD Cowen, and Canaccord Genuity serving as co-managers for the offering.
CeriBell, Inc. (Nasdaq: CBLL), una società di tecnologia medica in fase commerciale, ha annunciato la determinazione del prezzo per la sua offerta pubblica iniziale ampliata. L'azienda offrirà 10,606,060 azioni di azioni ordinarie a un prezzo di offerta pubblica di $17.00 per azione. CeriBell ha anche concesso agli underwriter un'opzione di 30 giorni per acquistare fino a un ulteriore 1,590,909 azioni al prezzo di offerta iniziale.
La negoziazione delle azioni è prevista per iniziare sul Nasdaq Global Select Market l'11 ottobre 2024, con il simbolo ticker 'CBLL'. I proventi lordi dell'offerta sono previsti essere circa $180.3 milioni, escluse eventuali esercitazioni dell'opzione degli underwriter. Si prevede che l'offerta si chiuda il 15 ottobre 2024, soggetta alle condizioni di chiusura consuete.
BofA Securities e J.P. Morgan agiscono come gestori congiunti e rappresentanti degli underwriter, con William Blair, TD Cowen e Canaccord Genuity che svolgono il ruolo di co-gestori per l'offerta.
CeriBell, Inc. (Nasdaq: CBLL), una empresa de tecnología médica en etapa comercial, ha anunciado el precio de su oferta pública inicial ampliada. La compañía está ofreciendo 10,606,060 acciones de acciones ordinarias a un precio de oferta pública de $17.00 por acción. CeriBell también ha otorgado a los suscriptores una opción de 30 días para comprar hasta 1,590,909 acciones adicionales al precio de oferta inicial.
Se espera que la negociación de las acciones comience en el Nasdaq Global Select Market el 11 de octubre de 2024, bajo el símbolo de cotización 'CBLL'. Se anticipa que los ingresos brutos de la oferta sean aproximadamente $180.3 millones, excluyendo cualquier ejercicio de la opción de los suscriptores. Se espera que la oferta se cierre el 15 de octubre de 2024, sujeto a las condiciones de cierre habituales.
BofA Securities y J.P. Morgan están actuando como gerentes de libros conjuntos y representantes de los suscriptores, siendo William Blair, TD Cowen y Canaccord Genuity los co-gestores de la oferta.
CeriBell, Inc. (Nasdaq: CBLL)는 상업적 단계의 의료 기술 회사로서, 확대된 기업 공개의 가격을 발표했습니다. 이 회사는 10,606,060 주식의 보통주를 주당 $17.00의 공모가로 제공할 예정입니다. CeriBell은 또한 인수인에게 초기 공모가로 추가 1,590,909 주식를 구매할 수 있는 30일 옵션을 부여했습니다.
주식 거래는 2024년 10월 11일에 Nasdaq Global Select Market에서 시작될 것으로 예상되며, 해당 티커 기호는 'CBLL'입니다. 이번 공모의 총 수익은 약 $180.3 백만으로 예상되며, 인수인의 옵션 행사 시 수익 제외됩니다. 이번 공모는 2024년 10월 15일에 종료될 것으로 예상되며, 일반적인 종료 조건이 적용됩니다.
BofA Securities와 J.P. Morgan은 공동 북런닝 매니저 및 인수인의 대표로 활동하며, William Blair, TD Cowen 및 Canaccord Genuity가 공모의 공동 매니저로서 역할을 맡고 있습니다.
CeriBell, Inc. (Nasdaq: CBLL), une entreprise de technologie médicale à un stade commercial, a annoncé le prix de son offre publique initiale agrandie. L'entreprise propose 10,606,060 actions ordinaires à un prix d'offre publique de 17,00 $ par action. CeriBell a également accordé aux souscripteurs une option de 30 jours pour acheter jusqu'à 1,590,909 actions supplémentaires au prix d'offre initial.
Il est prévu que la négociation des actions commence sur le Nasdaq Global Select Market le 11 octobre 2024, sous le symbole boursier 'CBLL'. Les produits bruts de l'offre devraient atteindre environ 180,3 millions $, sans tenir compte de l'exercice de l'option des souscripteurs. La clôture de l'offre est prévue pour le 15 octobre 2024, sous réserve des conditions de clôture habituelles.
BofA Securities et J.P. Morgan agissent en tant que gestionnaires conjointement responsables et représentants des souscripteurs, avec William Blair, TD Cowen et Canaccord Genuity servant de co-gestionnaires pour l'offre.
CeriBell, Inc. (Nasdaq: CBLL), ein Unternehmen für Medizintechnologie in der Handelsphase, hat die Preisfestsetzung für sein vergrößertes öffentliches Angebot bekannt gegeben. Das Unternehmen bietet 10.606.060 Aktien zum öffentlichen Angebotspreis von 17,00 $ pro Aktie an. CeriBell hat den Underwritern zudem eine 30-tägige Option eingeräumt, bis zu 1.590.909 zusätzliche Aktien zum anfänglichen Angebotspreis zu kaufen.
Der Handel der Aktien wird voraussichtlich am 11. Oktober 2024 an der Nasdaq Global Select Market unter dem Tickersymbol 'CBLL' beginnen. Die Bruttoeinnahmen aus dem Angebot werden auf etwa 180,3 Millionen $ geschätzt, ohne Berücksichtigung der Ausübung der Option der Underwriter. Der Abschluss des Angebots wird für den 15. Oktober 2024 erwartet, vorbehaltlich der üblichen Abschlussbedingungen.
BofA Securities und J.P. Morgan fungieren als gemeinsame Buchführer und Vertreter der Underwriter, während William Blair, TD Cowen und Canaccord Genuity als Co-Manager für das Angebot tätig sind.
- Upsized initial public offering indicates strong investor interest
- Gross proceeds expected to be approximately $180.3 million
- Listing on Nasdaq Global Select Market enhances company visibility
- Underwriters granted option to purchase additional shares, potentially increasing proceeds
- Potential dilution of existing shareholders' ownership
- Increased public scrutiny and reporting requirements as a public company
- Market volatility may affect stock price post-IPO
Insights
CeriBell's IPO pricing at
The IPO valuation and size are noteworthy for a commercial-stage medtech company, suggesting confidence in CeriBell's technology and market potential. The involvement of major underwriters like BofA Securities and J.P. Morgan adds credibility to the offering.
Investors should consider:
- CeriBell's focus on neurological conditions, a growing market segment
- The company's transition from pre-revenue to commercial stage
- Potential for rapid growth but also increased scrutiny as a public company
- Use of proceeds and path to profitability
This IPO represents a significant liquidity event for early investors and provides CeriBell with capital for expansion and R&D. However, new investors should carefully evaluate the company's financials and growth prospects before making investment decisions.
BofA Securities and J.P. Morgan are acting as joint book-running managers and as representatives of the underwriters for the offering. William Blair, TD Cowen and Canaccord Genuity are acting as co-managers for the offering.
The offering is being made only by means of a prospectus. Copies of the final prospectus relating to this offering, when available, may be obtained from BofA Securities, Attention: Prospectus Department, NC1-022-02-25, 201 North Tryon Street,
A registration statement on Form S-1, including a prospectus, relating to these securities was declared effective by the
About Ceribell
Ceribell is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Ceribell System is an AI-powered, rapidly deployable point-of-care electroencephalography ("EEG") platform designed to address the unmet needs of patients in the acute care setting. The company is headquartered in
INVESTOR CONTACT
Brian Johnston or Laine Morgan
Gilmartin Group, LLC
investors@ceribell.com
MEDIA CONTACT
Corrie Rose
Press@ceribell.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ceribell-inc-announces-pricing-of-upsized-initial-public-offering-302273634.html
SOURCE Ceribell, Inc.
FAQ
What is the IPO price for CeriBell (CBLL) stock?
How many shares is CeriBell (CBLL) offering in its IPO?
When will CeriBell (CBLL) stock begin trading on the Nasdaq?
What are the expected gross proceeds from CeriBell's (CBLL) IPO?
Who are the underwriters for CeriBell's (CBLL) initial public offering?
